Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 77 out of 100. How common it is

Topic: Risk, prevention and care in population studies

Plain-language summary

This large meta-analysis pooled dozens of studies to estimate how many people under age 65 are living with dementia worldwide. The researchers found roughly 3.9 million people globally have young-onset dementia, roughly double earlier estimates, with rates climbing steeply from the early 30s to the early 60s. It highlights a group of patients who are often missed or misdiagnosed because dementia is usually thought of as a disease of old age.

What this study adds

Evidence grade: Moderate

This is a pooled review of 2,760,379 participants. Roughly 3.9 million people worldwide under age 65 are living with young-onset dementia, about double earlier estimates, with rates climbing steeply from the early 30s to the early 60s. Its stated limit: Substantial heterogeneity existed across the pooled studies in case-ascertainment methods and diagnostic criteria, and most underlying studies came from high-income countries, limiting generalizability to low- and middle-income settings.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Hendriks, S., Peetoom, K., Bakker, C., et al. (2021). Global Prevalence of Young-Onset Dementia: A Systematic Review and Meta-analysis. JAMA Neurology. https://doi.org/10.1001/jamaneurol.2021.2161

Vancouver

Hendriks S, Peetoom K, Bakker C, et al. Global Prevalence of Young-Onset Dementia: A Systematic Review and Meta-analysis. JAMA Neurology. 2021. doi:10.1001/jamaneurol.2021.2161. PMID: 34279544.

BibTeX

@article{hendriks2021-4479c0b0,
  author  = {Hendriks, S. and Peetoom, K. and Bakker, C. and others},
  title   = {{Global Prevalence of Young-Onset Dementia: A Systematic Review and Meta-analysis}},
  journal = {JAMA Neurology},
  year    = {2021},
  doi     = {10.1001/jamaneurol.2021.2161},
  pmid    = {34279544},
  url     = {https://doi.org/10.1001/jamaneurol.2021.2161}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

Roughly 3.9 million people worldwide under age 65 are living with young-onset dementia, about double earlier estimates, with rates climbing steeply from the early 30s to the early 60s. This highlights a group of patients often missed or misdiagnosed because dementia is usually thought of as a disease of old age.

Study details

Limitations

Substantial heterogeneity existed across the pooled studies in case-ascertainment methods and diagnostic criteria, and most underlying studies came from high-income countries, limiting generalizability to low- and middle-income settings.

How this study scored 77/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record left out, no data; Study design 12 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 3 of 5; Sample size 4 of 4; Effect reported 2 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited left out, no data; Citations per year left out, no data; Impact for its field and year left out, no data; Cited by studies here 0 of 6; Still being cited left out, no data; Senior author's track record left out, no data; Institution's track record left out, no data; Multicenter collaboration left out, no data; Indexed in PubMed 2 of 2; Free to read left out, no data. 48 of the 62 points it could be judged on, which is 77 of 100. Total 77 of 100.48 of the 62 points we could judge = 77 of 100

Published in a leading specialty journal, and it is a meta-analysis pooling many studies. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 48 of the 62 points we could judge it on, which is 77 out of 100.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (JAMA Neurology)
Journal's citation record — / 4 No journal record from OpenAlex — left out of this score
Study design 12 / 12 A meta-analysis pooling many studies
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 3 / 5 2021 — within 6 year(s) of the newest study here
Sample size 4 / 4 2,760,379 participants
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 A review of other studies — randomization is not credited here
Times cited — / 7 No citation count (not found in OpenAlex) — left out of this score
Citations per year — / 5 No citation count or no year — left out of this score
Impact for its field and year — / 6 No field-weighted citation impact (OpenAlex has none yet) — left out of this score
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited — / 4 No yearly citation counts — left out of this score
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record — / 3 No institution listed in OpenAlex — left out of this score
Multicenter collaboration — / 3 Institutions not listed — left out of this score
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 34279544)
Free to read — / 2 Access not recorded — left out of this score
Points 48 / 62 Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 48 of the 62 points we could judge it on is 77 out of 100.
Total 77 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 24.

Later studies that cite this one

31 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in How common it is from nearby years

Also tagged “prevalence”

1,225 studies in the library carry the topic tag “prevalence”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,225 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on How common it is

See all studies in How common it is →